In an industry where innovation often outpaces infrastructure, the ability to translate scientific breakthroughs into scalable, consumer-ready products remains one of the greatest challenges and opportunities. For TOSLA, the B Corp-certified global leader in next-generation CDMO solutions, that challenge has become its defining strength.
With the launch of its new headquarters, TOSLA 3 Super Factory, an advanced R&D ecosystem, the company is entering a new chapter of growth, evolving its legacy of continuous innovation. This bold phase extends beyond nutricosmetics into the broader nutraceutical landscape, redefining how ingestible wellness products are developed, manufactured and brought to market.
Evolving Beyond Nutricosmetics
TOSLA has long been recognized as a leader in liquid nutricosmetics, an emerging category that bridges beauty and ingestible wellness. As consumer demand shifts toward longevity, prevention, and daily health optimization, the lines between beauty-from-within and broader nutraceutical solutions are increasingly blurred.
Today, TOSLA is strategically expanding its scope to encompass full-spectrum nutraceutical innovation. This evolution represents a structural shift rather than a simple category expansion. By applying its expertise in liquid delivery systems, clinical validation, and sensorial formulation, TOSLA is positioned to address a key gap in the market: the disconnect between efficacy and adherence. While traditional formats like capsules, powders, and gummies often fall short in palatability, compliance, or potency, liquid formats offer a unique advantage, transforming supplementation into a daily ritual.
At the core of this shift is a simple but powerful premise: efficacy alone is not enough, and consistency drives outcomes.
Scaling Innovation: The Launch of TOSLA 3 and Pavlina Headquarters
To support this expanded vision, TOSLA has made a significant investment in infrastructure.
The launch of the TOSLA 3 Super Factory and its new Pavlina headquarters marks a major milestone in the company’s growth trajectory. Designed to meet increasing global demand, the facility dramatically expands production capabilities, with total capacity reaching up to 45 million units annually.
The TOSLA 3 Super Factory was announced in 2023.Courtesy of TOSLA
But scale, for TOSLA, is not just about volume; it is also about readiness. By maintaining production utilization below 40%, the company ensures immediate availability for fast-growing partners and new product launches. This proactive capacity strategy allows brands to move quickly from concept to commercialization without the bottlenecks that often hinder growth in the CDMO space.
The new headquarters also centralizes TOSLA’s operations, integrating manufacturing, R&D, and strategic development under one roof, creating a seamless ecosystem designed for speed, precision, and collaboration.
“At TOSLA, innovation doesn’t begin with a trend – it begins with infrastructure. Our new R&D ecosystem and proprietary Library allow us to translate complex science into scalable, real-world solutions with unprecedented speed and precision,” says Uroš Gotar, Chief Innovation Officer. “The lab is where possibility becomes product. By centralizing clinical data, ingredient intelligence, and regulatory frameworks into a single system, we’ve created an environment where innovation is not only accelerated, but engineered for global scalability. In this way, we are able to eliminate the gap between discovery and delivery, so innovation can move as fast as the market demands, shaping the future of nutraceutical development.”
Advancing R&D: A New Lab and Intelligence-Driven Development
At the heart of TOSLA’s expansion is a state-of-the-art R&D and New Product Development (NPD) facility, alongside the introduction of its proprietary R&D Library – the intelligence engine of the company.
The R&D Library centralizes ingredient intelligence, clinical data, stability testing,
Alongside formulation and manufacturing, TOSLA is also investing in expanded packaging capabilities.Courtesy of TOSLA
The result is a fundamentally different approach to product development, one that bridges the gap between research and manufacturing. Rather than reacting to trends, TOSLA is building a framework for predictive innovation, allowing partners to develop products that are not only market-ready, but future-proof.
Expanding Packaging and Logistics Capabilities
Alongside formulation and manufacturing, TOSLA is also investing in expanded packaging capabilities, an often-overlooked but critical component of scalability. By broadening its packaging options and integrating these capabilities into its R&D process, TOSLA enables brand partners to align product performance with consumer experience at every touchpoint, from formulation to final delivery.
Looking ahead, the company is also developing a new logistics center, designed to further streamline global distribution and reduce lead times. This expansion reflects a broader understanding that in today’s market, speed and reliability are as essential as innovation itself.
Collaboration as a Catalyst: Partnership with Geltor
TOSLA’s growth is not happening in isolation. Strategic partnerships remain central to its model, particularly when it comes to translating breakthrough science into real-world applications. A defining example is its collaboration with Geltor, a leader in biodesigned proteins and peptides.
Together, the companies launched the first Vegan Signaling Collagen Shot, powered by PrimaColl®, a biomimetic type 21 signaling collagen.
While the ingredient itself represents a significant advancement in collagen science, the true innovation lies in its execution. TOSLA transformed a complex biotech ingredient into a ready-to-drink, great-tasting liquid format, leveraging its proprietary VELIOUS™ Flavor Technology to ensure palatability without added sugar. This sensorial dimension is critical in addressing one of the category’s most persistent challenges: adherence.
The result is a product that delivers clinically validated benefits, while fitting seamlessly into daily life, illustrating TOSLA’s ability to bridge the gap between scientific innovation and consumer behavior.
A New Standard for CDMO Partnerships
As the nutraceutical and beauty-from-within markets continue to converge, brands are increasingly seeking partners who can offer more than manufacturing. They need collaborators who can:
- Translate complex science into viable products
- Validate claims through clinical research
- Deliver scalable production without compromising quality
- Create formulations that consumers will use consistently
TOSLA’s model—combining clinical rigor, sensorial design, and scalable infrastructure—positions it uniquely within this landscape.
By integrating R&D, manufacturing, and strategic development, the company moves beyond the traditional CDMO role into something more comprehensive: a co-creation partner for next-generation wellness products.
Looking Ahead
With the launch of its new facilities and expanded capabilities, TOSLA is redefining its category. From liquid nutricosmetics to full-spectrum nutraceuticals, from formulation to logistics, from biotech partnerships to clinical validation, the company is building an end-to-end ecosystem designed for the future of ingestible wellness.
In a market increasingly defined by performance, transparency, and user experience, TOSLA’s approach reflects a deeper understanding of what drives success: innovation that people actually use. And in that distinction lies the next evolution of the category and the industry as a whole.
Disclaimer:
The above paid-for content was produced by and posted on behalf of the Sponsor. Content provided is generated solely by the Sponsor or its affiliates, and it is the Sponsor’s responsibility for the accuracy, completeness and validity of all information included. Skin Inc. takes steps to ensure that you will not confuse sponsored content with content produced by Skin Inc. and governed by its editorial policy.
